vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Legacy Education Inc. (LGCY). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $19.2M, roughly 1.0× Legacy Education Inc.). Legacy Education Inc. runs the higher net margin — 10.6% vs -177.4%, a 188.1% gap on every dollar of revenue. On growth, Legacy Education Inc. posted the faster year-over-year revenue change (40.7% vs -11.5%). Legacy Education Inc. produced more free cash flow last quarter ($512.7K vs $-23.1M).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.

LAB vs LGCY — Head-to-Head

Bigger by revenue
LAB
LAB
1.0× larger
LAB
$19.6M
$19.2M
LGCY
Growing faster (revenue YoY)
LGCY
LGCY
+52.2% gap
LGCY
40.7%
-11.5%
LAB
Higher net margin
LGCY
LGCY
188.1% more per $
LGCY
10.6%
-177.4%
LAB
More free cash flow
LGCY
LGCY
$23.6M more FCF
LGCY
$512.7K
$-23.1M
LAB

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
LAB
LAB
LGCY
LGCY
Revenue
$19.6M
$19.2M
Net Profit
$-34.7M
$2.0M
Gross Margin
48.5%
Operating Margin
-168.5%
13.3%
Net Margin
-177.4%
10.6%
Revenue YoY
-11.5%
40.7%
Net Profit YoY
-28.8%
46.0%
EPS (diluted)
$-0.09
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LGCY
LGCY
Q4 25
$19.2M
Q3 25
$19.6M
$19.4M
Q2 25
$21.8M
$18.0M
Q1 25
$40.8M
$18.6M
Q4 24
$13.6M
Q3 24
$22.1M
$14.0M
Q2 24
$22.5M
Q1 24
$45.5M
Net Profit
LAB
LAB
LGCY
LGCY
Q4 25
$2.0M
Q3 25
$-34.7M
$2.2M
Q2 25
$-33.5M
$1.2M
Q1 25
$-26.0M
$2.8M
Q4 24
$1.4M
Q3 24
$-26.9M
$2.1M
Q2 24
$-45.7M
Q1 24
$-32.2M
Gross Margin
LAB
LAB
LGCY
LGCY
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
LGCY
LGCY
Q4 25
13.3%
Q3 25
-168.5%
13.9%
Q2 25
-118.1%
11.1%
Q1 25
-80.8%
19.7%
Q4 24
12.2%
Q3 24
-120.9%
19.1%
Q2 24
-134.5%
Q1 24
-132.2%
Net Margin
LAB
LAB
LGCY
LGCY
Q4 25
10.6%
Q3 25
-177.4%
11.3%
Q2 25
-153.7%
6.8%
Q1 25
-63.8%
15.2%
Q4 24
10.3%
Q3 24
-122.0%
14.9%
Q2 24
-203.3%
Q1 24
-70.6%
EPS (diluted)
LAB
LAB
LGCY
LGCY
Q4 25
$0.15
Q3 25
$-0.09
$0.16
Q2 25
$-0.09
$0.07
Q1 25
$-0.07
$0.21
Q4 24
$0.10
Q3 24
$-0.07
$0.21
Q2 24
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LGCY
LGCY
Cash + ST InvestmentsLiquidity on hand
$129.4M
$21.1M
Total DebtLower is stronger
$660.3K
Stockholders' EquityBook value
$399.7M
$46.1M
Total Assets
$539.6M
$73.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LGCY
LGCY
Q4 25
$21.1M
Q3 25
$129.4M
$20.6M
Q2 25
$158.6M
$20.3M
Q1 25
$150.9M
$17.3M
Q4 24
$16.9M
Q3 24
$210.6M
$21.5M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
LGCY
LGCY
Q4 25
$660.3K
Q3 25
$776.9K
Q2 25
$1.4M
Q1 25
$1.0M
Q4 24
$1.1M
Q3 24
$55.2M
$758.2K
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
LGCY
LGCY
Q4 25
$46.1M
Q3 25
$399.7M
$43.7M
Q2 25
$424.5M
$41.0M
Q1 25
$454.6M
$39.3M
Q4 24
$36.4M
Q3 24
$489.3M
$32.6M
Q2 24
$510.3M
Q1 24
$577.3M
Total Assets
LAB
LAB
LGCY
LGCY
Q4 25
$73.1M
Q3 25
$539.6M
$72.1M
Q2 25
$557.0M
$69.2M
Q1 25
$579.6M
$67.1M
Q4 24
$62.1M
Q3 24
$681.5M
$50.6M
Q2 24
$708.7M
Q1 24
$777.7M
Debt / Equity
LAB
LAB
LGCY
LGCY
Q4 25
0.01×
Q3 25
0.02×
Q2 25
0.03×
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.11×
0.02×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LGCY
LGCY
Operating Cash FlowLast quarter
$-22.2M
$1.1M
Free Cash FlowOCF − Capex
$-23.1M
$512.7K
FCF MarginFCF / Revenue
-118.1%
2.7%
Capex IntensityCapex / Revenue
4.5%
2.8%
Cash ConversionOCF / Net Profit
0.52×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$4.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LGCY
LGCY
Q4 25
$1.1M
Q3 25
$-22.2M
$1.1M
Q2 25
$-20.7M
$3.0M
Q1 25
$-30.3M
$918.7K
Q4 24
$659.0K
Q3 24
$-27.9M
$3.2M
Q2 24
$-39.0M
Q1 24
$-62.5M
Free Cash Flow
LAB
LAB
LGCY
LGCY
Q4 25
$512.7K
Q3 25
$-23.1M
$809.7K
Q2 25
$-22.6M
$2.9M
Q1 25
$-35.3M
$596.6K
Q4 24
$466.8K
Q3 24
$-30.1M
$2.9M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
LAB
LAB
LGCY
LGCY
Q4 25
2.7%
Q3 25
-118.1%
4.2%
Q2 25
-103.6%
16.2%
Q1 25
-86.6%
3.2%
Q4 24
3.4%
Q3 24
-136.4%
21.1%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
LAB
LAB
LGCY
LGCY
Q4 25
2.8%
Q3 25
4.5%
1.3%
Q2 25
8.7%
0.5%
Q1 25
12.4%
1.7%
Q4 24
1.4%
Q3 24
10.2%
1.7%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
LAB
LAB
LGCY
LGCY
Q4 25
0.52×
Q3 25
0.48×
Q2 25
2.45×
Q1 25
0.33×
Q4 24
0.47×
Q3 24
1.52×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LGCY
LGCY

Segment breakdown not available.

Related Comparisons